Metagenomi Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the fiscal quarter ended September 30, 2026, disclosing share count and company classification status as of that period.
Key Highlights
- Shares outstanding: As of November 6, 2026, the registrant had 37,805,669 shares of common stock, $0.0001 par value per share, outstanding.
- Exchange listing: Common stock trades on The Nasdaq Global Select Market under the symbol MGX.
- Company classifications: The registrant is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC definitions.
- Extended transition period: The registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.
- Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
- Filing compliance: The registrant confirmed it has filed all reports required during the preceding 12 months and has been subject to filing requirements for the past 90 days.
Metagenomi Therapeutics Files Third Quarter 2026 Report with SEC
Metagenomi Therapeutics, Inc., a Delaware-incorporated genome editing company headquartered at 5959 Horton Street, 7th Floor, Emeryville, California 94608, filed its quarterly report covering the period ended September 30, 2026, according to the filing. The company's common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Global Select Market under the trading symbol MGX (NASDAQ:MGX). The Commission File Number assigned to the registrant is 001-41949.
As of November 6, 2026, the registrant reported 37,805,669 shares of common stock outstanding, according to the cover page of the filing. The company disclosed its classifications under SEC rules: it is a non-accelerated filer, a smaller reporting company, and an emerging growth company. The registrant also indicated it has elected not to use the extended transition period available to emerging growth companies for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
The filing contains forward-looking statements, which the company characterized as subject to known and unknown risks, uncertainties, and other factors that "may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements." The company stated these forward-looking statements represent its views as of the date of the filing, and noted it has "no current intention" of updating them except as required by applicable law. The quarterly report covers financial statements, management's discussion and analysis, market risk disclosures, and other required items as listed in the table of contents.
What Was Disclosed
Metagenomi Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 37,805,669 shares of common stock outstanding as of November 6, 2026, its Nasdaq listing under MGX, and its classifications as a non-accelerated filer, smaller reporting company, and emerging growth company.




Please wait processing your request...